106615-33-2Relevant academic research and scientific papers
HETEROCYCLIC COMPOUND DERIVATIVES AND MEDICINES
-
Page 31, (2010/02/05)
The present invention provides a compound which is useful as a PGI2 receptor agonist, and a pharmaceutical composition. The present invention is directed to a pharmaceutical composition comprising a compound represented by the following formula [1]: (R1 and R2 are the same or different and each represents optionally substituted aryl, Y represents N or CH, Z represents N or CH, A represents NH, NR5, O, S, or ethylene, R5 represents alkyl, D represents alkylene or alkenylene, E represents phenylene or single bond, G represents O, S, or CH2, R3 and R4 are the same or different and each represents hydrogen or alkyl, Q represents carboxy, alkoxycarbonyl, tetrazolyl, carbamoyl, or N-(alkylsulfonyl)carbamoyl), or a pharmaceutically acceptable salt thereof as an active ingredient.
Synthesis and bioactivities of novel pyridazine derivatives: Inhibitors of interleukin-1 beta (IL-1β) production
Matsuda, Takayuki,Aoki, Taro,Ohgiya, Tadaaki,Koshi, Tomoyuki,Ohkuchi, Masao,Shigyo, Hiromichi
, p. 2369 - 2372 (2007/10/03)
New pyridazine derivatives were prepared, and their abilities to inhibit IL-1β production were evaluated. Some compounds showed potent inhibitory activity against IL-1β production in HL-60 cells stimulated with lipopolysaccharide (LPS). The synthesis and structure-activity relationships of these compounds are described.
Anti-platelet aggregation activity of some pyrazines
Ohta, Akihiro,Takahashi, Hiromitsu,Miyata, Naoomi,Hirono, Hiroyuki,Nishio, Toyotaka,Uchino, Etsuo,Yamada, Kenji,Aoyagi, Yutaka,Suwabe, Yasushi,Fujitake, Masayuki,Suzuki, Takahiro,Okamoto, Kazuo
, p. 1076 - 1081 (2007/10/03)
This report describes the anti-platelet aggregation activity of 48 pyrazines. Among alkyl- and arylpyrazines tested, 2,3-diphenylpyrazines showed the strongest anti-platelet aggregation activity. Then, various substituents were introduced into the phenyl groups, and the 2,3-bis(p- methoxyphenyl)pyrazine derivatives were consequently found to possess considerably strong inhibitory activity.
Pyrazine derivatives useful as platelet aggregation inhibitors
-
, (2008/06/13)
Novel pyrazine derivatives are disclosed. The compounds possess a potent platelet aggregation-inhibiting activity and are effective for preventing diseases caused by aggregation of the platelet, for example, myocardial infarction and cerebral thromobsis.
